Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters

Xenobiotica

Volumn 41, Issue 9, 2011, Pages 752-757

  Picard, Nicolas ^a,b,c   Levoir, Laure ^a,b   Lamoureux, Fabien ^a,b   Yee, Sook Wah ^d   Giacomini, Kathleen M ^d   Marquet, Pierre ^a,b,c  

^a INSERM   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF LIMOGES   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

drug interaction; mammalian target of rapamycin; mTOR inhibitors; Transporters

Indexed keywords

CYCLOSPORIN; ESTRONE SULFATE; EVEROLIMUS; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1A2; ORGANIC ANION TRANSPORTER 1B1; ORGANIC ANION TRANSPORTER 1B3; RAPAMYCIN; TACROLIMUS; TRITIUM; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN CACO 2; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PROTEIN BINDING; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; INTESTINE CELL; LIVER CELL; PROTEIN EXPRESSION;

CACO-2 CELLS; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HEK293 CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INHIBITORY CONCENTRATION 50; INTESTINES; LIVER; ORGANIC ANION TRANSPORTERS; PROBENECID; SIROLIMUS; TRANSFECTION;

MAMMALIA;

EID: 79961203098     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.573882     Document Type: Article

References (25)

1. Aliabadi AZ, Mahr S, Dunkler D, Grömmer M, Zimpfer D, Wolner E, Grimm M, Zuckermann AO. (2008).Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation. Transplantation 86:1771-1776.
2. Annaert P, Ye ZW, Stieger B, Augustijns P. (2010).Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40:163-176.
3. Campone M, Levy V, Bourbouloux E, Berton Rigaud D, Bootle D, Dutreix C, Zoellner U, Shand N, Calvo F, Raymond E. (2009).Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer 100:315-321.
4. Crowe A, Lemaire M. (1998).In vitro and in situ absorption of SDZRAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res 15:1666-1672. (Pubitemid 28524574)
5. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantinevon Kaeppler HA, Starling RC, Sørensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P; RAD B253 Study Group. (2003).Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349:847-858. (Pubitemid 37025404)
6. Fehrenbach T, Cui Y, Faulstich H, Keppler D. (2003).Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol 368:415-420. (Pubitemid 37491501)
7. Franke RM, Scherkenbach LA, Sparreboom A. (2009). Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics 10:339-344.
8. Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, Fisher K, Fossati L, Hovenkamp E, Korjamo T, Masungi C, Maubon N, Mols R, Müllertz A, Mönkkönen J, O'Driscoll C, Oppers-Tiemissen HM, Ragnarsson EG, Rooseboom M, Ungell AL. (2008).Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci 35:383-396.
9. Kalliokoski A, Niemi M. (2009).Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693-705.
10. Kovarik JM, Hartmann S, Hubert M, Berthier S, Schneider W, Rosenkranz B, Rordorf C. (2002).Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol 42:222-228. (Pubitemid 34101356)
11. Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, Fardel O. (2006).Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur J Pharm Sci 28:109-117.
12. Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, Maes BD. (2005).Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 5:2236-2243. (Pubitemid 41648471)
13. Mulders P. (2009).Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. BJU Int 104:1585-1589.
14. Niemi M. (2007).Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8:787-802. (Pubitemid 47288978)
15. Oswald S, Nassif A, Modess C, Keiser M, Hanke U, Engel A, Lütjohann D, Weitschies W, Siegmund W. (2010).Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther 87:663-667.
16. Picard N, Yee SW, Woillard JB, Lebranchu Y, Le Meur Y, Giacomini KM, Marquet P. (2010).The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther 87:100-108.
17. Rothenburger M, Teerling E, Bruch C, Lehmkuhl H, Suwelack B, Bara C, Wichter T, Hinder F, Schmid C, Stypmann J. (2007).Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant 26:250-257. (Pubitemid 46341888)
18. Ruiz JC, Sánchez A, Rengel M, Beneyto I, Plaza JJ, Zárraga S, Errasti P, Andrés A, Morales JM, Torregrosa JV, Alarcón A, Morey A, Romero R, Fernández A, Díaz JM, Cantarell C; EVERODATA Group. (2007). Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: preliminary results of the EVERODATA registry. Transplant Proc 39:2157-2159. (Pubitemid 47418218)
19. Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, Tsuji A. (2006).Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3- sulfate by human intestinal Caco-2 cells. Drug Metab Dispos 34:1423-1431. (Pubitemid 44079886)
20. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. (1992).Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 20:753-761.
21. Sauvage FL, Gaulier JM, Lachtre G, Marquet P. (2006).A fully automated turbulent-flow liquid chromatography-tandem mass spectrometry technique for monitoring antidepressants in human serum. Ther Drug Monit 28:123-130. (Pubitemid 44391706)
22. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. (2003).Inhibition of transporter-mediated hepatic uptake as a mechanism for drugdrug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610-616. (Pubitemid 36152336)
23. Shitara Y, Sato H, Sugiyama Y. (2005).Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 45:689-723. (Pubitemid 40261822)
24. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW. (2004).Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:167-177. (Pubitemid 39013406)
25. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. (2010).Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28:69-76.